Overview of Cloperax

What is Cloperax? Quick Facts and Definition

The drug Cloperax is an antitussive agent containing the synthetic compound Cloperastine, intended for the symptomatic relief of persistent dry cough. Cloperax is specifically recognized for its liquid formulations designed for oral intake.

Property	Description
Active ingredient	Cloperastine (typically as the Fendizoate salt)
Form	Oral suspension or syrup
Pharmacological class	Antitussive Agent
Common use	Symptomatic relief of dry cough
Origin	Synthetic

What Type of Medicine is Cloperax?

Cloperax is a synthetic pharmaceutical preparation categorized as an antitussive agent (ATC Code R05DB21). This medication's fundamental purpose is to suppress the cough reflex, addressing the physical act of coughing itself.

It belongs to the category of non-narcotic antitussives. Unlike some older cough remedies, it achieves its primary effect without using opioid derivatives. Cloperastine acts by suppressing the central drive to cough. The compound's action focuses on modulating the neural pathways that initiate coughing without the specific central nervous system depressant risks associated with narcotics.

Cloperastine Composition and Available Form

The active ingredient in Cloperax is Cloperastine (INN), typically supplied as the salt Cloperastine Fendizoate within an oral suspension or syrup. As a single-active-ingredient product, its composition is centered entirely on the cough-suppressing molecule. The selection of Cloperastine Fendizoate is a key feature, as this salt form is utilized in liquid products for its favorable stability.

Cloperax is contained in an aqueous base, formulated as a palatable suspension or syrup suitable for oral intake. Cloperastine exhibits dual central and peripheral activity, differentiating it from purely central agents. This means the medicine acts to calm the cough reflex both where it originates and in the airways.

General Purpose: How Cloperax Relieves a Cough

The general purpose of Cloperax is to provide relief by acting as a cough suppressant specifically targeting the nonproductive or dry cough. Its high-level mechanism involves exerting a central antitussive effect, where it directly influences the body’s cough control system.

Cloperastine works by modulating the cough center, which is located within the brain's medulla oblongata, effectively raising the threshold necessary to trigger an involuntary cough. This action is the core reason why the drug helps interrupt the cycle of sustained irritation and allows symptomatic relief for a persistent dry cough.

What side effects are possible with Cloperax?

Possible side effects and safety information

The official safety profile for Cloperax (Cloperastine) details potential adverse reactions based on their classified frequency and the body system affected, as documented by national regulatory authorities.

Frequency-Classified Adverse Reactions The majority of listed non-beneficial effects are classified as Uncommon, meaning they are documented to occur in less than 1 in 100 individuals. These uncommon effects primarily affect the following System-Organ Classes:

Nervous System Disorders: Includes somnolence (drowsiness) and dizziness.
Gastrointestinal Disorders: Includes effects such as dry mouth and other gastric disturbances.
Immune System Disorders: Potential for allergic reactions (hypersensitivity) is also documented.

Serious Adverse Reactions and Safety Cautions While no specific common adverse reaction is listed as inherently serious, regulatory information highlights specific constraints and high-level risks:

Hepatic Impairment: Caution is required when the medicine is administered to patients with severe hepatic impairment, reflecting the drug’s metabolism.
Interaction Risk: The official label notes that Cloperax may enhance the sedative effect when taken concomitantly with alcohol or other CNS depressants (central nervous system depressants).
Contraindication: The medication is contraindicated in individuals with known hypersensitivity to the active substance or its excipients.
Special Populations: Due to the risk of drowsiness, caution is advised when performing tasks requiring full alertness, such as driving or operating machinery. Use during lactation is not recommended as regulatory data confirming excretion into human milk is unavailable.

The regulatory safety structure emphasizes managing the risk of sedation and identifying patient populations with specific physiological limitations.

Overdose and Emergency Response

The official regulatory profile for Cloperax (Cloperastine) overdose details the specific clinical signs that may appear following the ingestion of quantities much higher than the therapeutic dose. The documented presentation primarily involves effects on the central nervous system (CNS) and manifestations consistent with anticholinergic toxicity.

Documented Manifestations and Outcomes

Overdose may present with symptoms such as marked drowsiness, excitation, hallucinations, generalized anticholinergic symptoms, ataxia (lack of motor coordination), and potentially severe outcomes. The most critical manifestation documented in regulatory documents is the occurrence of convulsions.

When to Seek Urgent Medical Help

Immediate medical attention must be sought in all cases of suspected overdose, particularly if doses significantly exceeding the instructed amount have been consumed. This is mandatory due to the potential for severe neurological effects.

Official Management and Monitoring

Management protocols mandated in regulatory documents emphasize reducing absorption and providing supportive care. Treatment procedures include taking measures like inducing vomiting or performing stomach lavage with saline serum to mitigate intoxication. Treatment is defined as symptomatic and maintenance treatment, as the official labeling indicates that no specific antidote is known. Clinical observation and continuous monitoring are necessary throughout the management period.

Therapeutic Uses of Cloperax

What Cloperax Treats: Main Uses and Benefits

Cloperax is used in situations involving certain distressing symptoms by providing symptomatic relief for the non-productive, dry cough associated with various respiratory issues. This medication is used in contexts involving inflammatory or irritative states, specifically when the cough lacks functional purpose.

This medication is commonly used across conditions characterized by periods of heightened symptoms, specifically addressing symptoms that create noticeable physiological strain. It is generally applied in settings that involve acute or unstable symptom patterns, such as coughs linked to the common cold, upper respiratory infections, or the dry phase of bronchitis.

The supportive benefit offered is to assist with the easing of cough frequency and intensity, especially when symptoms escalate to a level that creates significant discomfort. Assistance with night-time coughing episodes supports the patient in coping more steadily with difficult episodes and contributes to improved day-to-day comfort.

“Symptomatic relief supports the patient in coping more steadily with difficult episodes and contributes to improved day-to-day comfort.”

Quick Fact: Symptomatic Relief for Persistent Dry Cough

Regulatory References

clinical overview of cloperastine in cough treatment

Eligibility and Restrictions for Use

The use of Cloperax is strictly defined by regulatory eligibility criteria established in official government documentation.

Absolute Non-Eligibility (Contraindications)

Cloperax is contraindicated for patients with a known hypersensitivity or allergy to the active ingredient, cloperastine, to any excipients, or to related antihistaminic agents. Absolute regulatory restrictions also apply to individuals currently receiving concomitant treatment with Monoamine Oxidase Inhibitors (MAOIs). Use is also contraindicated in patients with conditions like hereditary fructose intolerance if the specific formulation contains relevant excipients.

Age and Reproductive Status Restrictions

Cloperax is explicitly contraindicated in children under 2 years of age. Eligibility is established for children aged 2 to 12 years under specific guidance, and for adults and adolescents over 12 years. The drug is not recommended for use during pregnancy or breastfeeding, as safety in these physiological states has not been definitively established in official documentation.

Conditional Use (Caution Required)

Regulatory documents mandate caution when Cloperax is used by older adults due to potential increased sensitivity. Caution is also required for patients with pre-existing conditions that may be affected by the drug's properties, including intraocular hypertension (glaucoma), prostatic hypertrophy leading to urine retention, or severe cardiovascular diseases.

What should I know about interactions with other medicines?

Cloperax Interactions with other medicines and products

Official regulatory documents structure the interaction profile for Cloperax (cloperastine) primarily around the risk of enhanced Central Nervous System (CNS) depression resulting from co-administration with specific substance categories. These are classified as clinically significant interactions where restrictions or caution are required.

Interaction Domain	Interacting Categories & Restrictions
CNS Depressants	Co-administration with medicinal products that cause drowsiness, sedation, or depress the central nervous system (e.g., certain sedatives, hypnotics, tranquilizers, or other cough/cold preparations) requires caution due to the risk of additive effects.
Alcohol	Avoidance is required for co-administration with alcoholic beverages, as alcohol has additive depressant effects on the CNS. This combination may increase the risk of impaired coordination, dizziness, and excessive drowsiness.
Anticholinergic Drugs	Use with caution when combined with other drugs possessing anticholinergic properties (such as certain antidepressants or antipsychotics), due to the potential for an additive anticholinergic burden.

The officially documented interaction information mandates that healthcare providers assess the use of any concurrent CNS-acting agents or alcohol to minimize the risk of increased CNS depression. This framework of constraints—explicitly listing alcohol avoidance and the need for caution with CNS depressants—defines the essential component of the product’s official interaction profile as stated in government-level regulatory documents.

Mechanism of Action

Cloperax (cloperastine) functions as a centrally-acting modulator with auxiliary peripheral actions. Its primary activity involves interaction within the central nervous system, specifically targeting the cough center located in the medulla oblongata of the brainstem. . By an incompletely elucidated mechanism, cloperastine modifies the neural activity of the ascending and descending pathways that mediate the cough reflex, serving as a non-narcotic inhibitor of this pathway.

Additionally, cloperastine acts as a direct antagonist at histamine H1 receptors in peripheral tissues, which are Gq protein-coupled receptors. This interaction blocks the binding of histamine, thereby modulating the signaling cascade initiated by H1 receptor activation. Furthermore, the molecule exhibits weak anticholinergic properties, acting as an antagonist at muscarinic acetylcholine receptors. This reduces the parasympathetic nervous system's influence on smooth muscle and glandular tissues. The systemic physiological consequences include a direct reduction in the efferent neural drive from the medullary cough center and peripheral modulation of smooth muscle contractility and glandular secretion within the respiratory tract.

Dosage and Administration Information

The administration of Cloperax follows specific instructions to ensure standardized use across populations. This product is formulated as an oral suspension, which is the intended route of administration. Dosage is volume-based, measured in milliliters (ml), requiring the use of a calibrated device for accuracy.

Administration Scope

Instruction	Detail
Route of administration:	Oral.
Dosing schedule (Adults/Adolescents >12 years):	10 ml of the 3.54 mg/ml oral suspension per dose.
Timing in relation to meals:	Administration is preferably before meals.
Preparation requirements:	The bottle containing the suspension must be shaken before use.
Age-group administration rules:	Children 6-12 years: 5 ml three times daily.
	Children 2-6 years: 2.5 ml three times daily.
	The medicine is not specified for use in children under two years of age.

Instruction Classifications (High-Level)

Classification	Detail
Administration method type:	Liquid Oral suspension.
Frequency pattern:	Three times daily (TID), typically administered morning, noon, and night.
Administration basis:	Standardized regimens for use.
Use-context constraints:	Intended for short-term symptomatic management.

Connection to the overall use protocol (2–4 sentences): The medication involves a fixed, volume-based dosing protocol that dictates the oral route and a consistent three-times daily frequency, often taken before meals, over a short course of treatment. The use protocol is further structured by specific, age-dependent volume doses for pediatric patients, which must be measured precisely using a calibrated instrument.

Recent Clinical Evidence

Clinical Studies for Dry Cough Symptom Patterns

Research has examined Cloperax (Cloperastine) in the context of persistent, non-productive (dry) cough associated with conditions characterized by acute or disruptive episodes. Scientists utilized randomized, placebo-controlled clinical trials to investigate how patient-reported symptoms change over short time intervals.

Studies reported measurements showing patterns related to cough frequency and symptom intensity when compared to placebo. Research also explored functional outcomes; for instance, patterns in night rest metrics were observed when compared to those who received a placebo. Comparative studies have examined Cloperax alongside other non-narcotic antitussives, contributing to the broader evidence landscape and helping to contextualize findings within its therapeutic class.

Populations and Study Duration

The primary research base for Cloperax centered on adult outpatients experiencing coughing related to acute or chronic respiratory conditions. Observational research has also examined its use in pediatric populations. The majority of the available research is derived from short-term trials, with follow-up durations often limited to short intervals, reflecting the study context involving episodic symptom patterns.

Research Gaps and Uncertainty

Evidence highlights what is known—and what is still uncertain. Long-term effects are not fully established, as there is limited information for outcomes beyond short-term use. Furthermore, the available data remain heterogeneous, and research exploring direct, high-quality comparisons with other alternatives remains limited. Findings describe group patterns, but certainty regarding performance relative to other medicines is low.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Cloperax (FAQ)

Q: Is Cloperax considered an antihistamine as well as a cough suppressant?

A: The official product information indicates that the active ingredient, Cloperastine, is primarily a non-narcotic cough suppressant (antitussive). However, it also acts as an antagonist at histamine H1 receptors, meaning it has documented antihistamine properties in addition to its main cough-suppressing action.

Q: Does Cloperax have a dual mechanism of action, or is it only centrally acting?

A: Regulatory documents describe Cloperax as working through a combined mechanism. While it primarily exerts a central antitussive effect (on the cough center), it also has peripheral activity by blocking H1-receptors and providing mild anticholinergic effects. This activity profile suggests the compound influences the cough reflex both centrally and peripherally.

Q: Can Cloperax cause changes in heart rate or blood pressure?

A: Specific heart rate changes are not listed as common side effects. However, official information advises caution for patients with severe cardiovascular diseases. This warning is related to the drug's known anticholinergic properties, as this class of medicine can affect the cardiovascular system.

Q: How long does it take for Cloperax to start working after taking it?

A: According to official pharmacological data, the cough-suppressing effect of Cloperax typically begins to appear within approximately 20 to 30 minutes after oral administration. This onset time is listed in official documents as a typical pattern for symptomatic relief.

Q: Can Cloperax be taken on an empty stomach, or does food affect its absorption?

A: Official regulatory prescribing information advises that administration is recommended preferably before meals. However, official product information does not strictly prohibit use with food.

Q: What happens if I miss a dose of Cloperax?

A: General guidance for scheduled medication is to take a missed dose as soon as it is remembered. Patients are advised not to take a double dose to make up for the forgotten one, as this increases the risk of side effects.

Q: Can older adults safely use Cloperax for chronic cough?

A: Official information states that use in older adults requires caution due to potential increased sensitivity. The medicine is intended for short-term symptomatic management only and is not specified for the long-term treatment of chronic cough.

Q: Can Cloperax be used for coughs related to asthma or COPD?

A: Cloperax is indicated for the symptoms of a non-productive (dry) cough. Some regulatory information notes that caution is required for individuals with respiratory conditions like asthmatic cough or respiratory failure.

Q: What do researchers say about the long-term safety of Cloperax?

A: Official product information states that clinical research is primarily based on short-term trials with limited follow-up periods. Consequently, the effects and safety profile of Cloperax for long-term use are not fully established in regulatory documents.

Q: Is Cloperax used in other countries under different brand names?

A: The active ingredient in Cloperax, Cloperastine, is a globally recognized compound. It is marketed in various countries under different brand names, such as Sekisan, Seki, and Flutox.

Q: Can Cloperax cause stomach upset or other gastrointestinal issues?

A: Official safety data lists potential side effects affecting the gastrointestinal system, though they are considered uncommon. These can include dry mouth and other gastric disturbances, which covers issues like stomach upset.

Q: Is an allergic reaction to Cloperax possible, and what are the signs?

A: The potential for allergic reactions (hypersensitivity) is documented and is an absolute contraindication. Documented signs of a possible allergic reaction may include fever, rash, and swelling.

Q: Does Cloperax affect sleep quality?

A: The drug is associated with the uncommon side effect of somnolence (drowsiness). Clinical data also suggest an influence on night rest metrics, indicating the medication may influence sleep patterns.

Q: What is the general recommended duration of treatment with Cloperax?

A: The official warning and precaution sections confirm that treatment is intended for short-term symptomatic management only, typically no more than 5 to 7 days.

Q: Will Cloperax interact with over-the-counter cold and flu products?

A: Official interaction warnings advise caution when Cloperax is taken alongside other medicinal products that cause sedation or depress the central nervous system (CNS). Some over-the-counter cold and flu medicines contain CNS depressants, requiring caution if co-administered.

Q: Does Cloperax have any anticholinergic effects?

A: Official pharmacological information notes that Cloperastine exhibits weak anticholinergic properties.

Q: Can Cloperax cause dizziness or unsteadiness?

A: Yes, dizziness is listed as an Uncommon adverse reaction in official safety data, and this effect may lead to feelings of unsteadiness.

Q: Does the time of day I take Cloperax matter for its effectiveness?

A: The official dosing schedule requires the medication to be taken consistently three times daily (TID). This frequency is important for maintaining consistent therapeutic levels and ensuring the drug's effectiveness throughout the day and night.

Q: How quickly is Cloperax eliminated from the body?

A: Official pharmacokinetic data indicates that the active ingredient, Cloperastine, is eliminated primarily through urine, with a half-life of approximately 2.16 hours.

Q: Does Cloperax have any effect on the respiratory center?

A: According to official pharmacological information, Cloperax's primary action is on the cough center in the brain, but it does not depress the respiratory center. This distinguishes it from certain older, opioid-based cough suppressants.

Q: Can Cloperax cause blurred vision or other eye issues?

A: Official information advises caution for patients who have intraocular hypertension (glaucoma). This warning is due to the drug's anticholinergic properties.

Q: Are there specific food or drink types that should be avoided with Cloperax?

A: The official product information explicitly advises avoidance of alcoholic beverages. Alcohol has additive depressant effects on the central nervous system, which may increase the risk of impaired coordination and excessive drowsiness.

Q: Does Cloperax contain any ingredients that might be a concern for people with specific allergies (beyond the active ingredient)?

A: Yes, regulatory documents list excipients (inactive ingredients) that may be potential allergens for some individuals. For instance, some formulations may contain preservatives like Methyl parahydroxybenzoate (E-218) or Propyl parahydroxybenzoate (E-216).

Q: Is it possible for Cloperax to stop working after long-term use?

A: Cloperax is a non-narcotic antitussive and is officially noted as being devoid of dependence or addiction phenomena. Since it is intended for short-term use, the development of tolerance or loss of effect is not a primary concern addressed in the regulatory profile.

Q: What is the ATC code for Cloperax's active ingredient?

A: The active ingredient, Cloperastine, is classified by the World Health Organization's Anatomical Therapeutic Chemical (ATC) system. Its specific code is R05DB21.

Q: Are there different formulations of Cloperax, like tablets versus syrup?

A: The product is generally supplied as an oral suspension or syrup, which is the focus of the official regulatory information. While the active ingredient may be available in other forms internationally, the primary regulatory dosage form is the liquid formulation.

Q: Does Cloperax help with productive coughs (with mucus) or only dry coughs?

A: Cloperax is indicated only for treating symptoms of a non-productive (dry) cough. It is not intended for productive coughs, and some regulatory information may advise against its use for certain cough types that involve mucus.

Q: What should I do if a side effect of Cloperax becomes very bothersome?

A: Official patient guidance states that if a suspected side effect becomes serious or bothersome, the course of action is to stop taking the medicine and consult a doctor. This is particularly important if any signs of an allergic reaction are observed.

How should Cloperax be stored and disposed of?

How to Store and Dispose of Cloperax (Cloperastine Fendizoate Oral Suspension)

The official storage conditions for Cloperax oral suspension are established to maintain its stability and effectiveness, as mandated by regulatory documents.

Storage Requirements

Condition	Requirement
Temperature	Store at a temperature not exceeding 30°C.
Protection	Keep the product in the original container, tightly closed, to protect the liquid from direct sunlight, heat, and moisture.
Child Safety	The medicine must be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired Cloperax must be disposed of according to local regulations and guidelines. It is officially advised to dispose of the product at an approved waste disposal plant and to take precautions to prevent the medicine from entering waterways or sewer systems.

Cloperax